COVID-19 Vaccine and Treatment Strategy

Our COVID-19 Vaccine and Treatment Strategy supports access to, and delivery of, safe and effective COVID-19 vaccines and treatments, as soon as they are available.

COVID-19 vaccination logo – no tag

The Pfizer/BioNTech vaccine has been provisionally approved by the Therapeutic Goods Administration (TGA) for individuals 16 years and older.

Learn more about COVID-19 vaccines.


About the strategy

The strategy outlines how we are investing in promising vaccines and treatments and how we can provide them to Australians.

Why it is important

The strategy is helping to speed up access to safe and effective vaccines or treatment that are available and affordable to all Australians. 

This will reduce the health, social and economic impacts of the COVID-19 pandemic. It will help save lives and livelihoods.


Our goal is early access to, and delivery, of safe and effective COVID-19 vaccines and treatments for all Australians.

To do this, the strategy is focusing on 5 key areas.

Research and development

We are identifying and supporting world-leading research activities to speed up the development and manufacture of promising COVID-19 vaccines and treatments.

Purchase and manufacturing

We are building a diverse global portfolio of investments to seek to secure early access to promising vaccines and treatments. Opportunities to use and strengthen local manufacturing are being sought as part of investment decisions.

International partnerships

We are working with organisations and countries around the world to accelerate development of a safe and effective vaccine and treatments for COVID-19.

It is important that access to vaccines and treatments is available and affordable to all people. To help achieve this, we are working closely with our neighbours across the Pacific and South East Asia, focusing on immunisation policy and coverage.

Regulation and safety

We will use Therapeutic Goods Administration (TGA) regulatory pathways to enable early access to COVID-19 vaccines and treatments. The TGA will work with international counterparts, sharing information on vaccine clinical trials, manufacturing and safety. This will ensure a safe and fast regulatory process for Australia and our region.

Immunisation administration and monitoring

Australians will receive safe and effective vaccines under a targeted and responsive national COVID-19 vaccination policy and immunisation program. Policies and programs will be based on up-to-date health advice.

Meeting our goals

Researchers and companies across the world are developing potential vaccines for COVID-19. The Australian Government is working closely with developers to track vaccine progress and provide access for Australians if vaccines are successful. Read more in the Prime Minister’s media release.

The Australian Government has agreements for the supply of COVID-19 vaccines, if they are proved to be safe and effective, with:

Read more about the supply production agreements.

Australians now have access to a suite of potential COVID-19 vaccines by joining the international COVAX Facility. Read more about our commitment.

The Australian Government is providing funding for new COVID-19 research through the Medical Research Future Fund. Read more about the clinical trials funding and vaccine development funding.

    Who we work with

    To achieve our goals we are working with:

    Learn more

    Learn more about:


    Department of Health National Office

    For all general enquiries, comments and concerns

    enquiries [at]
    Postal addresses: 
    GPO Box 9848
    Canberra ACT 2601

    View contact

    Last updated: 
    27 January 2021

    Help us improve

    If you would like a response please use the enquiries form instead.